A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs TTI 622 (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Nivolumab; Pembrolizumab; Rituximab
  • Indications Lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Trillium Therapeutics Inc
  • Most Recent Events

    • 14 Jun 2018 According to a Trillium Therapeutics media release, dosing has been initiated.
    • 22 May 2018 Status changed from planning to recruiting.
    • 10 Apr 2018 According to a Trillium Therapeutics media release, the first patient expected to be dosed in Q2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top